Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 176

1.

Protective effects of GLP-1 on glomerular endothelium and its inhibition by PKCβ activation in diabetes.

Mima A, Hiraoka-Yamomoto J, Li Q, Kitada M, Li C, Geraldes P, Matsumoto M, Mizutani K, Park K, Cahill C, Nishikawa S, Rask-Madsen C, King GL.

Diabetes. 2012 Nov;61(11):2967-79. doi: 10.2337/db11-1824. Epub 2012 Jul 23.

2.

Glucagon-like peptide-1 receptor agonist inhibits asymmetric dimethylarginine generation in the kidney of streptozotocin-induced diabetic rats by blocking advanced glycation end product-induced protein arginine methyltranferase-1 expression.

Ojima A, Ishibashi Y, Matsui T, Maeda S, Nishino Y, Takeuchi M, Fukami K, Yamagishi S.

Am J Pathol. 2013 Jan;182(1):132-41. doi: 10.1016/j.ajpath.2012.09.016. Epub 2012 Nov 14.

PMID:
23159951
3.

Exendin-4 Ameliorates Lipotoxicity-induced Glomerular Endothelial Cell Injury by Improving ABC Transporter A1-mediated Cholesterol Efflux in Diabetic apoE Knockout Mice.

Yin QH, Zhang R, Li L, Wang YT, Liu JP, Zhang J, Bai L, Cheng JQ, Fu P, Liu F.

J Biol Chem. 2016 Dec 16;291(51):26487-26501. Epub 2016 Oct 26.

PMID:
27784780
4.

Effects of selenium and exendin-4 on glucagon-like peptide-1 receptor, IRS-1, and Raf-1 in the liver of diabetic rats.

Barakat GM, Moustafa ME, Bikhazi AB.

Biochem Genet. 2012 Dec;50(11-12):922-35. doi: 10.1007/s10528-012-9532-2. Epub 2012 Sep 16.

PMID:
22983684
5.

Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice.

Rieg T, Gerasimova M, Murray F, Masuda T, Tang T, Rose M, Drucker DJ, Vallon V.

Am J Physiol Renal Physiol. 2012 Oct;303(7):F963-71. doi: 10.1152/ajprenal.00259.2012. Epub 2012 Jul 25.

6.

GLP-1 signals via ERK in peripheral nerve and prevents nerve dysfunction in diabetic mice.

Jolivalt CG, Fineman M, Deacon CF, Carr RD, Calcutt NA.

Diabetes Obes Metab. 2011 Nov;13(11):990-1000. doi: 10.1111/j.1463-1326.2011.01431.x.

7.

The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential.

Fujita H, Morii T, Fujishima H, Sato T, Shimizu T, Hosoba M, Tsukiyama K, Narita T, Takahashi T, Drucker DJ, Seino Y, Yamada Y.

Kidney Int. 2014 Mar;85(3):579-89. doi: 10.1038/ki.2013.427. Epub 2013 Oct 23.

PMID:
24152968
8.

Protein kinase Cβ mediates downregulated expression of glucagon-like peptide-1 receptor in hypertensive rat renal arteries.

Liu L, Liu J, Gao Y, Ng CF, Yu X, Dou D, Huang Y.

J Hypertens. 2015 Apr;33(4):784-90; discussion 790. doi: 10.1097/HJH.0000000000000480.

PMID:
25915883
9.

Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes.

Kodera R, Shikata K, Kataoka HU, Takatsuka T, Miyamoto S, Sasaki M, Kajitani N, Nishishita S, Sarai K, Hirota D, Sato C, Ogawa D, Makino H.

Diabetologia. 2011 Apr;54(4):965-78. doi: 10.1007/s00125-010-2028-x. Epub 2011 Jan 21.

PMID:
21253697
10.

Enhancing the GLP-1 receptor signaling pathway leads to proliferation and neuroprotection in human neuroblastoma cells.

Li Y, Tweedie D, Mattson MP, Holloway HW, Greig NH.

J Neurochem. 2010 Jun;113(6):1621-31. doi: 10.1111/j.1471-4159.2010.06731.x. Epub 2010 Apr 2.

11.

Protection of exendin-4 analogue in early experimental diabetic retinopathy.

Zhang Y, Wang Q, Zhang J, Lei X, Xu GT, Ye W.

Graefes Arch Clin Exp Ophthalmol. 2009 May;247(5):699-706. doi: 10.1007/s00417-008-1004-3. Epub 2008 Dec 16.

PMID:
19084986
12.

Glucagon-like peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor.

Ban K, Kim KH, Cho CK, Sauvé M, Diamandis EP, Backx PH, Drucker DJ, Husain M.

Endocrinology. 2010 Apr;151(4):1520-31. doi: 10.1210/en.2009-1197. Epub 2010 Feb 19.

PMID:
20172966
13.

Glucagon-like peptide 1 prevents reactive oxygen species-induced endothelial cell senescence through the activation of protein kinase A.

Oeseburg H, de Boer RA, Buikema H, van der Harst P, van Gilst WH, Silljé HH.

Arterioscler Thromb Vasc Biol. 2010 Jul;30(7):1407-14. doi: 10.1161/ATVBAHA.110.206425. Epub 2010 May 6.

14.

Differential importance of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide 1 receptor signaling for beta cell survival in mice.

Maida A, Hansotia T, Longuet C, Seino Y, Drucker DJ.

Gastroenterology. 2009 Dec;137(6):2146-57. doi: 10.1053/j.gastro.2009.09.004. Epub 2009 Sep 17.

PMID:
19766644
15.

Acute activation of central GLP-1 receptors enhances hepatic insulin action and insulin secretion in high-fat-fed, insulin resistant mice.

Burmeister MA, Ferre T, Ayala JE, King EM, Holt RM, Ayala JE.

Am J Physiol Endocrinol Metab. 2012 Feb 1;302(3):E334-43. doi: 10.1152/ajpendo.00409.2011. Epub 2011 Nov 15.

16.

The murine glucagon-like peptide-1 receptor is essential for control of bone resorption.

Yamada C, Yamada Y, Tsukiyama K, Yamada K, Udagawa N, Takahashi N, Tanaka K, Drucker DJ, Seino Y, Inagaki N.

Endocrinology. 2008 Feb;149(2):574-9. Epub 2007 Nov 26.

PMID:
18039776
17.

Puerarin Protects Pancreatic β-Cells in Obese Diabetic Mice via Activation of GLP-1R Signaling.

Yang L, Yao D, Yang H, Wei Y, Peng Y, Ding Y, Shu L.

Mol Endocrinol. 2016 Mar;30(3):361-71. doi: 10.1210/me.2015-1213. Epub 2016 Jan 20.

18.

Glucagon-like peptide-1 and its receptor agonist exendin-4 modulate cholangiocyte adaptive response to cholestasis.

Marzioni M, Alpini G, Saccomanno S, Candelaresi C, Venter J, Rychlicki C, Fava G, Francis H, Trozzi L, Glaser S, Benedetti A.

Gastroenterology. 2007 Jul;133(1):244-55.

PMID:
17631146
19.

Glucagon-like peptide-1 (GLP-1) reduces mortality and improves lung function in a model of experimental obstructive lung disease in female mice.

Viby NE, Isidor MS, Buggeskov KB, Poulsen SS, Hansen JB, Kissow H.

Endocrinology. 2013 Dec;154(12):4503-11. doi: 10.1210/en.2013-1666. Epub 2013 Oct 3.

PMID:
24092637
20.

Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway.

Gupta NA, Mells J, Dunham RM, Grakoui A, Handy J, Saxena NK, Anania FA.

Hepatology. 2010 May;51(5):1584-92. doi: 10.1002/hep.23569.

Supplemental Content

Support Center